NCT02083185View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

March 26, 2014

Primary Completion Date

January 1, 2016

Study Completion Date

February 23, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Relugolix

Relugolix tablets

DRUG

Leuprorelin

Leuprorelin subcutaneous injection

Trial Locations (23)

Unknown

Birmingham

San Diego

Denver

Daytona Beach

Jeffersonville

Wichita

Shreveport

Omaha

Lawrenceville

Garden City

Syracuse

Cincinnati

Springfield

Lancaster

Myrtle Beach

Nashville

Dallas

San Antonio

Virginia Beach

Abbotsford

Vancouver

Montreal

Québec

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY